作者
J Peccatori, A Forcina, D Clerici, R Crocchiolo, L Vago, MTL Stanghellini, M Noviello, C Messina, A Crotta, A Assanelli, S Marktel, S Olek, S Mastaglio, F Giglio, L Crucitti, A Lorusso, E Guggiari, F Lunghi, M Carrabba, M Tassara, M Battaglia, A Ferraro, MR Carbone, G Oliveira, MG Roncarolo, S Rossini, M Bernardi, C Corti, M Marcatti, F Patriarca, M Zecca, F Locatelli, Claudio Bordignon, K Fleischhauer, Attilio Bondanza, C Bonini, Fabio Ciceri
发表日期
2015/2
期刊
Leukemia
卷号
29
期号
2
页码范围
396-405
出版商
Nature Publishing Group
简介
Hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA) haploidentical family donors is a promising therapeutic option for high-risk hematologic malignancies. Here we explored in 121 patients, mostly with advanced stage diseases, a sirolimus-based, calcineurin-inhibitor-free prophylaxis of graft-versus-host disease (GvHD) to allow the infusion of unmanipulated peripheral blood stem cell (PBSC) grafts from partially HLA-matched family donors (TrRaMM study, Eudract 2007-5477-54). Conditioning regimen was based on treosulfan and fludarabine, and GvHD prophylaxis on antithymocyte globulin Fresenius (ATG-F), rituximab and oral administration of sirolimus and mycophenolate. Neutrophil and platelet engraftment occurred in median at 17 and 19 days after HSCT, respectively, and full donor chimerism was documented in patients’ bone marrow since the first post-transplant …
学术搜索中的文章
J Peccatori, A Forcina, D Clerici, R Crocchiolo, L Vago… - Leukemia, 2015